

U.S.P.S. EXPRESS MAIL "POST OFFICE TO ADDRESSEE" SERVICE **DEPOSIT INFORMATION**

Express Mail Label No.: EV 653881042 US

Date of Deposit: 27 April 2005

BRINKS HOFER GILSON &LIONE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Baker et al.

Appln. No.:

09/943,780

Filed:

August 30, 2001

For:

SECRETED AND TRANSMEMBRANE

POLYPEPTIDES AND NUCLEIC ACIDS

ENCODING THE SAME

Attorney Docket No: 10466/129-2 (P2549P1C10-2)

Mail Stop RCE Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL

Art Unit: 1642

Examiner: Larry R. Helms

Sir:

Attac	hed	is	ar	e:
-------	-----	----	----	----

\boxtimes	Transmittal Letter (in dupl.); Request For Continued Examination (37 CFR Section 1.114) (in dupl.); Response and Request for Continued Examination with Appendix 1-6.
\boxtimes	Return Receipt Postcard
Fee c	alculation:
	No additional fee is required.
	Small Entity.
	An extension fee in an amount of \$ for amonth extension of time under 37 C.F.R. § 1.136(a)
\boxtimes	A petition or processing fee in an amount of \$790.00 under 37 C.F.R. § 1.17(e).
	An additional filing fee has been calculated as shown below:

					Sma	II Entity	<u> </u>	Not a S	mall Entity
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Add'l Fee	or	Rate	Add'I Fee
Total		Minus			x \$25=			x \$50=	
Indep.		Minus			X100=		<u> </u>	x \$200=	
First Pre	esentation of Multiple D	ep. Claim	1		+\$180=			+ \$360=	
					Total	\$	l	Total	\$

Fee payment	τ:
-------------	----

	A che	eck in th	ne amo	unt of \$	is	enclosed.	
6-2			_			00 4005 1 41	

Please charge Deposit Account No. 23-1925 in the amount of \$790.00. A copy of this Transmittal is \boxtimes enclosed for this purpose.

Payment by credit card in the amount of \$____ (Form PTO-2038 is attached).

The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper \boxtimes (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925.

Respectfully submitted,



U.S.P.S. EXPRESS MAIL "POST OFFICE TO ADDRESSEE" SERVICE **DEPOSIT INFORMATION**

Express Mail Label No.: EV 653881042 US

Date of Deposit: 27 April 2005

BRINKS HOFER GILSON &LIONE

Examiner: Larry R. Helms

Art Unit: 1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Baker et al.

Appln. No.: 09/943,780

Filed: August 30, 2001

For:

SECRETED AND TRANSMEMBRANE

POLYPEPTIDES AND NUCLEIC ACIDS

ENCODING THE SAME

Attorney Docket No: 10466/129-2 (P2549P1C10-2)

Mail Stop RCE Commissioner for Patents U.S. Patent and Trademark Office P. O. Box 1450 Alexandria, VA 22313-1450

REQUEST FOR CONTINUED EXAMINATION (37 C.F.R. § 1.114)

Sir:

Applicant(s) requests continued examination of the above-identified application under 37

C.F.		.114.	nt(s) requests continued examination of the above-identified application under 37					
\boxtimes	Sub	missio	ssion under 37 CFR 1.114 (check at least one of the following):					
		Prev	viously submitted:					
			Applicant(s) requests nonentry of any previously-filed unentered amendments.					
			Please enter and consider the Amendment After Final Under 37 C.F.R. §1.116 previously filed on					
			Consider the arguments in the Appeal Brief or Reply Brief previously filed or					
			Other:					
•	\boxtimes	Atta	ched is/are:					
			An Information Disclosure Statement					
		\boxtimes	An Amendment to the written description, claims, or drawings					
		\boxtimes	New Arguments and/or New Evidence in support of Patentability					
			Other:					

05/02/2005 SSESHE1 00000020 231925 09943780

	Req	uest for suspension of action:
	37 C	licant(s) hereby request suspension of action on the above-identified application under C.F.R. §1.103(c) for a period of months. (Period of suspension shall not exceed onths; requires Processing Fee under 37 C.F.R. §1.17(i)).
	Sma	all Entity Status:
		Applicant hereby asserts entitlement to claim small entity status under 37 CFR §§ 1.9 and 1.27.
		A small entity statement or assertion of entitlement to claim small entity status was filed in prior application no/ and such status is still proper and desired.
		Is no longer desired.
\boxtimes	Арр	licant(s) calculate the following fees to be due in connection with this Request:
	\boxtimes	A Request fee of \$790 under 37 C.F.R. §1.17(e).
		A suspension processing fee of \$ under 37 C.F.R. §1.17(i).
		An additional filing fee of \$ under 37 C.F.R. §1.16 (additional independent claims and/or additional total claims).
		An extension fee of \$ under 37 C.F.R. §1.17(a) for a 3-month extension of time.
\boxtimes	Fee	payment to cover the above-enumerated fee(s):
		A check in the amount of \$ is enclosed.
	\boxtimes	Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$790. A copy of this Request is enclosed for this purpose.
		A payment by credit card in the amount of \$ (Form PTO-2038 is attached).
		The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE). A copy of this Request is enclosed for this purpose.
		Respectfully submitted,
Date	la	C. Noel Kaman (Reg. No. 51,857)



U.S.P.S. EXPRESS MAIL "POST OFFICE TO ADDRESSEE" SERVICE DEPOSIT INFORMATION

Express Mail Label No.:	EV 653881042 US
-------------------------	-----------------

Date of Deposit: 27 April 2005

Our Case No. 10466-129 P2548P1C10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Baker et al.)
Serial No. 09/943,780) Examiner Larry R. Helms)
Filing Date: 08/30/2001) Group Art Unit No. 1642)
For: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC)))

RESPONSE AND REQUEST FOR CONTINUED EXAMINATION

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed January 27, 2005, the Applicants respectfully request reconsideration in light of the following remarks, and if necessary, continued examination of this application.

Amendments to the Specification begin on page 2 of this paper

Amendments to the Claims are reflected in the Listing of the Claims, which begins on page 3 of this paper.

Remarks / Arguments begin on page 5 of this paper.

Appl. No. 09/943,780 Amdmt. dated 27 April 2005 Reply to Office Action of 27 January 2005

Please amend the specification as follows:

Please amend the first paragraph on page 1, beginning at line 2 as follows:

This application is a continuation of, and claims priority under 35 USC §120 to. US Application 09/866028 filed 5/25/2001 (issued as U.S. Patent No. 6,642,360 on 11/4/2003), which is a continuation of and claims priority under 35 USC § 120 to, PCT Application PCT/US99/28301 filed 12/1/1999, which claims priority under 35 USC §119 to US Provisional Application 60/113296 filed 12/22/1998, where PCT/US99/28301 is a continuation in part of, and claims priority under 35 USC §120 to, US Application 09/254311 filed 3/3/1999, now abandoned, which is the National Stage filed under 35 USC §371 of PCT Application PCT/US98/25108 filed 12/1/1998, which claims priority under 35 USC §119 to US Provisional Application 60/069873 filed 12/17/1997. and where US Application 09/866,028 is also a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application PCT/US01/06520 filed 2/28/2001, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application PCT/US00/32678 filed 12/1/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application PCT/US00/20710 filed 7/28/2000, which claims priority under 35 USC §119 to US Provisional Application 60/146222 filed 7/28/1999, and where PCT Application PCT/US00/20710 is also a continuation-in-part of, and claims priority under 35 USC §120 to PCT Application PCT/US00/14042 filed 5/22/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application PCT/US00/08439 filed 3/30/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application PCT/US00/05841 filed 3/2/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application PCT/US00/04414 filed 2/22/2000, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application PCT/US00/03565 filed 2/11/00, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application PCT/US99/30095 filed 12/16/1999, which claims priority under 35 USC §119 to US Provisional Application 60/113296 filed 12/22/1998, and where PCT Appl. No. 09/943,780
Amdmt. dated 27 April 2005
Reply to Office Action of 37 Jan

Reply to Office Action of 27 January 2005

Application PCT/US99/30095 is also a continuation of, and claims priority under 35 USC §120 to, US Application 09/218517 filed 12/22/1998, and additionally where PCT Application PCT/US99/30095 is also a continuation-in-part of, and claims priority under 35 USC §120 to. PCT Application PCT/US99/28301 filed 12/1/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application PCT/US99/28409 filed 11/30/1999, which claims priority under 35 USC §119 to US Provisional Application 60/112850 filed 12/16/98, and where PCT Application PCT/US99/28409 is also a continuation of, and claims priority under 35 USC §120 to. US Application 09/216021 filed 12/16/1998, and additionally where PCT Application PCT/US99/28409 is also a continuation of, and claims priority under 35 USC §120 to. PCT Application PCT/US99/28313 filed 11/30/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application PCT/US99/21090 filed 9/15/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application PCT Application PCT/US99/12252 filed 6/2/1999, which is a continuation-in-part of, and claims priority under 35 USC §120 to, US Application 09/254311 filed 3/3/1999, where US Application 09/254311 is the National Stage filed under 35 USC §371 of PCT Application PCT/US98/25108 filed 12/1/1998, which is a continuation-in-part of, and claims priority under 35 USC §120 to, PCT Application PCT/US98/19330 filed 9/16/1998, which claims priority under 35 USC §119 to US 60/075945 filed 2/25/1998, 60/074092 filed 2/9/1998, Provisional Applications: 60/074086 filed 2/9/1998, 60/070440 filed 1/5/1998, 60/068017 filed 12/18/1997, 60/069873 filed 12/17/1997, 60/069870 filed 12/17/1997, 60/069702 filed 12/16/1997, 60/069696 filed 12/16/1997, 60/069694 filed 12/16/1997, 60/069425 filed 12/12/1997, 60/069335 filed 12/11/1997, 60/069334 filed 12/11/1997, 60/069278 filed 12/11/1997 and 60/067411 filed 12/3/1997.